文献速递眼底病与葡萄膜炎

点状内层脉络膜炎:双侧病变与脉络膜新生血管的发生率

Incidence of bilateral disease and choroidal neovascularisation in punctate inner choroiditis.
PubMed 文献 · Br J Ophthalmol · 2026-07-03

这项美国单中心回顾性病例系列纳入52例符合SUN标准的小点状内层脉络膜炎(PIC)患者,分析双侧受累和脉络膜新生血管(CNV)的发生率。诊断时59.6%为单侧病变,随访中11例出现对侧眼受累;诊断时46.6%眼存在CNV,随访中20眼发生新发CNV。免疫抑制与活动性CNV风险降低相关(OR 0.50,95%CI 0.27至0.93)。

要点

  • PIC诊断时多为单侧,但随访中对侧眼受累年发生率为0.08/人年。
  • CNV在诊断时常见(46.6%眼),随访中新发CNV年发生率为0.06/眼年。
  • 控制既往CNV后,免疫抑制与活动性CNV风险降低相关(OR 0.50)。

核心结论

  • PIC常以单侧起病,但存在双侧进展风险。
  • CNV在就诊时常见,是视力下降的原因之一。
  • 免疫抑制与活动性CNV风险降低相关。

研究设计与样本

  • 回顾性单中心病例系列,纳入美国三级转诊中心52例符合SUN标准的PIC患者。
  • 采用人年与眼年分母计算发生率,并以交错入组锚定PIC诊断。
  • 采用Kaplan-Meier法进行时间至事件分析,并用时间更新分析评估免疫抑制对活动性CNV的风险修饰作用。

主要发现

  • 诊断时31/52例(59.6%)为单侧病变。
  • 随访中11例出现对侧眼受累(0.08/人年;95%CI 0.04至0.13),诊断后5年内发生率最高(0.20/人年;95%CI 0.09至0.36)。
  • 接受免疫抑制治疗的4例单侧患者中,无一在治疗期间发生对侧眼病变。
  • 诊断时CNV存在于34/73眼(46.6%)。
  • 随访中20眼发生新发CNV(0.06/眼年;95%CI 0.04至0.10),诊断后5年内发生率最高(0.14/眼年;95%CI 0.08至0.22)。

关键数值与推荐

  • 控制既往CNV后,时间更新分析显示免疫抑制与活动性CNV风险降低相关(OR 0.50;95%CI 0.27至0.93)。
  • 10眼出现视力低于20/40,均与CNV相关;其中8眼经抗血管内皮生长因子治疗后改善至优于20/40。

临床怎么用

  • 对PIC患者应关注对侧眼受累风险,尤其在诊断后5年内。
  • 对PIC患者应评估CNV,因其在就诊时常见且可导致视力下降。
  • 免疫抑制可能降低活动性CNV风险,但需结合个体情况权衡。

局限性

  • 回顾性单中心设计,样本量52例,可能存在选择偏倚。
  • 免疫抑制与对侧眼受累的观察基于4例单侧患者,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To characterise the incidence of bilateral involvement and choroidal neovascularisation (CNV) in punctate inner choroiditis (PIC). METHODS: Retrospective, single-centre case series of 52 patients with PIC evaluated at a tertiary referral centre in the USA. Patients meeting Standardization of Uveitis Nomenclature criteria were included. Records were reviewed for laterality, CNV, treatment and visual outcomes. Incidence rates were calculated using person-year and eye-year denominators with staggered entry anchored at PIC diagnosis. Kaplan-Meier methods were used for time-to-event analyses. Time-updated analysis assessed immunosuppression as a risk modifier for active CNV. RESULTS: At diagnosis, 31/52 patients (59.6%) had unilateral disease. During follow-up, 11 developed fellow-eye involvement (0.08/person-year; 95% CI 0.04 to 0.13), with the highest incidence within 5 years of diagnosis (0.20/person-year; 95% CI 0.09 to 0.36). None of the four unilateral patients treated with immunosuppression developed fellow-eye disease while receiving therapy. At diagnosis, CNV was present in 34/73 eyes (46.6%). During follow-up, 20 eyes developed incident CNV (0.06/eye-year; 95% CI 0.04 to 0.10), highest within 5 years of diagnosis (0.14/eye-year; 95% CI 0.08 to 0.22). In time-updated analysis controlling for prior CNV, immunosuppression was associated with reduced odds of active CNV (OR, 0.50; 95% CI 0.27 to 0.93). 10 eyes developed visual acuity worse than 20/40, all associated with CNV; 8 improved to better than 20/40 after anti-vascular endothelial growth factor therapy. CONCLUSION: PIC frequently presents unilaterally but carries risk of bilateral progression. CNV is common at presentation and is a cause of vision loss. Immunosuppression is associated with reduced odds of active CNV.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Liberman P, Maturi JR, Thorne JE, et al. Incidence of bilateral disease and choroidal neovascularisation in punctate inner choroiditis. Br J Ophthalmol. 2026. PMID: 42399072. doi:10.1136/bjo-2026-329570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。